As of 2023 the technology to offer polygenic scores to consumers definitely exists.

This is judged as of February 2023. TRUE if by then the technology to compute and deliver polygenic scores to individuals existed and was in use, for example commercial services offering polygenic risk scores or polygenic embryo screening to paying customers, or validated published methods able to do so. MOSTLY TRUE if the technology existed but was offered only in limited or clinical settings rather than directly to consumers. MOSTLY FALSE if only research-stage methods existed and none had been deployed. FALSE if polygenic scoring could not be done at all as of 2023.

Set before the research began.

1. E1 Consumer genetic testing: expectation and reality - Genomics Education Programme Genomics Education Programme (NHS) · 15 January 2020

   “Polygenic risk scores offer a way to quantify the risk for some diseases, and many DTC tests now report them; but their predictive power should not be overestimated.”

2. E2 Consumer genetic testing: expectation and reality - Genomics Education Programme Genomics Education Programme (NHS) · 15 January 2020

   “Professor Lucassen explains in the podcast that the value of polygenic risk scores is currently limited to a public health setting – stratifying patients according to risk and treating them accordingly – rather than for individuals.”

E1 is a 2020 NHS Genomics Education Programme article, independent of the subject. It says polygenic risk scores "offer a way to quantify the risk for some diseases, and many DTC tests now report them." That means consumer services were already computing polygenic scores and giving them to individuals well before February 2023, which meets the TRUE criterion. E2 questions how useful these scores are for individuals, but it does not dispute that the technology existed and was being used.